Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis
Open Access
- 18 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9), e43056
- https://doi.org/10.1371/journal.pone.0043056
Abstract
Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Eight-week-old C57BL/6 mice were fed a methionine- and choline-deficient plus high fat (MCD+HF) diet with or without 0.1% metformin for 8 weeks. Co-administration of metformin significantly decreased fasting plasma glucose levels, but did not affect glucose tolerance or peripheral insulin sensitivity. Metformin ameliorated MCD+HF diet-induced hepatic steatosis, inflammation, and fibrosis. Furthermore, metformin significantly reversed hepatic steatosis and inflammation when administered after the development of experimental NASH. These histological changes were accompanied by reduced hepatic triglyceride content, suppressed hepatic stellate cell activation, and the downregulation of genes involved in fatty acid metabolism, inflammation, and fibrogenesis. Metformin prevented and reversed steatosis and inflammation of NASH in an experimental non-diabetic model without affecting peripheral insulin resistance.Keywords
This publication has 36 references indexed in Scilit:
- Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of Diabetic PatientsObesity, 2008
- The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patientsDiabetes Research and Clinical Practice, 2008
- Selective versus Total Insulin Resistance: A Pathogenic ParadoxCell Metabolism, 2008
- High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinaseHepatology, 2008
- Genes for systemic vascular complications are differentially expressed in the livers of Type 2 diabetic patientsDiabetologia, 2004
- Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1Diabetes, 2004
- Metformin reverses fatty liver disease in obese, leptin-deficient miceNature Medicine, 2000
- Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.2000
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal Of Gastroenterology, 1999
- Regulation of fatty acid synthase gene expression: an approach for reducing fat accumulationJournal of Animal Science, 1993